Cephalon

Executive Summary

Neuropharm R&D firm signs R&D and licensing agreement with Boston University for rights to key enzymes that may be partially responsible for development of amyloid plaques in Alzheimer's patients, West Chester, Pa.-based Cephalon announces. BU and the firm will work to identify the proteins and then design inhibitors to stop the development of amyloid plaques. New agreement should complement the $ 20 mil., five-year R&D agreement with Schering- Plough signed in June 1990 for development of brain protease inhibitors as Alzheimer's therapeutics. Cephalon said May 29 that it had received the second $ 5 mil. payment from the Schering agreement.